UBS cuts Cipla stock price target, keeps buy rating on Lanreotide shortage

Published 29/10/2024, 16:46
UBS cuts Cipla stock price target, keeps buy rating on Lanreotide shortage

On Tuesday, UBS maintained its Buy rating on Cipla Ltd. (CIPLA:IN) shares but reduced the price target from INR2,060.00 to INR1,960.00. The adjustment comes in light of the anticipated impact on near-term earnings due to shortages of Lanreotide, a drug in Cipla's portfolio.

Cipla has indicated that its third-quarter financial performance for fiscal year 2025 will be affected by these shortages, leading to a projected decline in U.S. sales for the December 2024 quarter to less than $220 million, down from $237 million in the second quarter of fiscal year 2025. The company has not produced Lanreotide for one to two months, which will influence the December 2024 quarter's results.

The pharmaceutical company expects sales to return to normal in the March 2025 quarter. Cipla clarified that there are no supply chain issues involved in the production of Lanreotide. Instead, the shortage is attributed to reduced production at a partner's facility, which is currently undergoing an expansion of its capacity to produce the drug. This expansion is one of the reasons for the current supply shortfall.

Cipla anticipates that the effects of the capacity enhancement at its partner's facility will become evident in the following year. The company remains optimistic that once the expansion is complete, production levels of Lanreotide will stabilize, alleviating the current constraints on supply and sales.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.